Pentostatin (2′-deoxycoformycin) for the treatment of lymphoid neoplasms
- 30 September 1990
- journal article
- clinical trial
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 17 (2-3) , 213-215
- https://doi.org/10.1016/0305-7372(90)90050-p
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Effectiveness of Pentostatin (2‘-Deoxycoformycin) in Refractory Lymphoid NeoplasmsScandinavian Journal of Haematology, 2009
- Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitorsJournal of Molecular Medicine, 1988
- 2′-Deoxycoformycin (Pentostatin) for Lymphoid MalignanciesAnnals of Internal Medicine, 1988
- Remissions in Hairy-Cell Leukemia with Pentostatin (2′-Deoxycoformycin)New England Journal of Medicine, 1987
- Low-dose deoxycoformycin in lymphoid malignancy.Journal of Clinical Oncology, 1985
- THERAPEUTIC SELECTIVITY OF AND PREDICTION OF RESPONSE TO 2'-DEOXYCOFORMYCIN IN ACUTE LEUKAEMIAThe Lancet, 1981
- The biochemical and clinical consequences of 2'-deoxycoformycin in refractory lymphoproliferative malignancyBlood, 1981
- REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIAThe Lancet, 1980
- A novel adenosine and ara‐a deaminase inhibitor, (R)‐3‐(2‐deoxy‐β‐D‐erythro‐pentofuranosyl)‐3,6,7,8‐tetrahydroimidazo[4,5 ‐d] [1,3]diazepin‐8‐olJournal of Heterocyclic Chemistry, 1974
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972